AAVX

ABIVAX Société Anonyme

AAVXF.US abivax.com
Healthcare · Biotechnology
139.00
+0.00 (+0.00%)
USD · PINK
52-week range
71.26
139.00
Trading at 100% of the 52-week range
Market Cap
12.13B
P/E Ratio
0.00
Forward P/E
0.94
Book Value
6.30
Div. Yield
N/A
% Institutions
47.53%
% Insiders
4.28%

1 Year

+66.8%

3 Year

+663.3%

10 Year

+1,472.4%
Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Information

▼
Company Name
ABIVAX Société Anonyme
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
ISIN: US00370M1036
Currency: USD
Full Time Employees: 80
Phone: 33 1 53 83 09 63
Website: abivax.com
Fiscal Year End: December
Description:

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Address:

7-11 Boulevard Haussmann, Paris, France, 75009

People

▼

Directors & Officers

Name Title Year Born
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 1958
Mr. Didier Blondel EVP, CFO & Board Secretary 1964
Mr. Patrick Malloy Senior VP & Head of Investor Relations NA
Ms. Ida Hatoum Chief People & Compliance Officer 1975
Mr. James Berger Global Head of Marketing NA
Mr. Pierre Courteille M.B.A. Chief Business Officer 1969
Mr. Jerome Denis Ph.D. Executive Vice President of Process Development & Manufacturing NA
Hema Keshava Senior Vice President of Finance NA
Chris Rabbat Ph.D. VP & Global Head of Medical Affairs NA
Kevin Shan Ph.D. VP & Global Head of Biometrics NA

Financial Highlights

▼
Market Cap: $12.13B
EBITDA: $-254.00M
Book Value: $6.30
Earnings/Share: $-5.37
Profit Margin: 0.00%
Operating Margin: -4,183.71%
ROA (TTM): -44.65%
ROE (TTM): -157.07%
Revenue (TTM): $4.92M
Revenue/Share (TTM): $0.07
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 35.20%

Valuation Metrics

Enterprise Value: $9.69B
Trailing P/E: 0.00
Forward P/E: 0.94

Shares Statistics

Shares Outstanding: 87.25M
Shares Float: 69.47M
% Insiders: 4.28%
% Institutions: 47.53%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.07M
Gross Profit
subtotal
$-1.07M
SG&A
adjust
$-72.64M
R&D
adjust
$-177.69M
Operating Income
subtotal
$-250.53M
Other / Non-Operating Items
adjust
$-85.44M
Net Income
subtotal
$-335.98M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AAVXF.US!